Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Paracrine effect of human adipose-derived stem cells on lymphatic endothelial cells.

Marcozzi C., Frattini A., Borgese M., Rossi F., Barone L., Solari E.

Animal Study, published in Regen Med (2020) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Regen Med (2020)
Country
England
Reported sample size
—
Source database
PubMed
PMID
33201769
DOI
10.2217/rme-2020-0071
Citations
15

Abstract (original English)

Aim: The proposal of this study was to evaluate, in vitro , the potential paracrine effect of human adipose-derived stem cells (hASCs) to promote lymphangiogenesis in lymphatic endothelial cells isolated from rat diaphragmatic lymphatic vessels. Materials & methods: ELISA on VEGFA, VEGFC and IL6 in hASC-conditioned medium; LYVE1 immunostaining; and gene expression of PROX1 , VEGFR3 , VEGFC, VEGFA and IL6 were the methods used. Results: In 2D culture, hASC-conditioned medium was able to promote lymphatic endothelial cell survival, maintenance of endothelial cobblestone morphology and induction to form a vessel-like structure. Conclusion: The authors' results represent in vitro evidence of the paracrine effect of hASCs on lymphatic endothelial cells, suggesting the possible role of hASC-conditioned medium in developing new therapeutic approaches for lymphatic system-related dysfunction such as secondary lymphedema.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AdipocytesAnimalsEndothelial CellsHumansLymphangiogenesisLymphatic VesselsRatsStem CellsVascular Endothelial Growth Factor CVascular Endothelial Growth Factor Receptor-3

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.